Change of name to Argent BioPharma Limited
2 April 2024
Argent BioPharma Ltd
Change of name to Argent BioPharma Limited
Argent BioPharma Ltd (Argent BioPharma or the Company), an innovative drug discovery company within the biopharmaceutical sector, has formally changed its name from MGC Pharmaceuticals Limited to Argent BioPharma Limited as approved by shareholders at a General Meeting held 18 March 2024.
Change of name to Argent BioPharma Ltd
The name change has been processed by the Australian Securities and Investments Commission and will take effect on the ASX from commencement of trading on Wednesday, 3 April 2024. The Company's ASX code will migrate to RGT.
The name change will have a delayed effective date in the UK due to additional regulatory requirements that can only be met after the effective date on the ASX, the anticipated effective date of change for the UK is 10 April 2024. The Company's new ISIN and TIDM are AU0000326647 and RGT respectively.
The Company's website address is now www.argentbiopharma.com.
Shareholders should note that their shareholdings will be unaffected by the change of name. Existing share certificates should be retained as they will remain valid for all purposes and no new share certificates will be issued.
Company Overview
In a notable milestone signalling the conclusion of its restructuring process, supported by a substantial injection of capital and a comprehensive operational transformation, Argent BioPharma is set to position itself as a significant player in pioneering drug discovery within the biopharmaceutical sector. With dual listings on both the London Stock Exchange and the Australian Stock Exchange, Argent BioPharma is poised to make a considerable impact in advancing medical treatment accessibility, harnessing sophisticated methodologies in PolyPharmacology and Nanotechnology.
As a key pillar of Argent BioPharma's philosophy, the Company embraces PolyPharmacology, an innovative methodology focused on crafting and implementing therapeutics to influence numerous molecular targets simultaneously. This approach plays a pivotal role in effectively tackling the intricacies of multifaceted diseases, thereby establishing a pioneering benchmark in both drug development and therapeutic effectiveness.
Operational Highlights
Argent BioPharma is positioned to generate revenue through its Investigational Medicinal Products (IMPs), CannEpil® and CimetrA®, which are accessible to patients through early access schemes in key markets including the UK, USA, and Europe. These initiatives are further supported by real-world data obtained from early access treatments, offering valuable insights into safety and efficacy that bolster clinical trial outcomes.
Argent BioPharma's European research hub is a key asset, playing a crucial role across the drug development continuum from conceptualisation to commercialisation. The hub operates from two distinct manufacturing facilities; one dedicated to clinical trials and early access programmes; and the other geared towards large-scale commercial production. Argent BioPharma adheres rigorously to stringent EU GMP and GDP guidelines.
Product Portfolio
Argent BioPharma places special emphasis on its product range targeting immunology and neurology, utilising PolyPharmacology to innovate novel treatments. Committed to addressing unmet medical needs, the Company aims to introduce new treatment every four years. Key products include CannEpil® for refractory epilepsy and cerebral palsy, CimetrA® for acute lung injury and ARDS, and CogniCann® for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development.
Roby Zomer, Managing Director and CEO of Argent BioPharma, commented: "As Argent BioPharma emerges from MGC Pharma, it is well positioned in the new era in biopharmaceuticals, committed to providing accessible and impactful healthcare solutions on a global scale. This rebranding signifies our commitment to innovation and advancement in the biopharmaceutical landscape. We are excited to leverage our expertise in PolyPharmacology and Nanotechnology to pioneer ground-breaking treatments, addressing unmet medical needs and driving positive change in global healthcare."
-Ends-
Authorised for release by the board of directors, for further information please contact:
|
Argent BioPharma Roby Zomer CEO & Managing Director +61 8 6382 3390
|
Argent BioPharma Rowan Harland Company Secretary +61 8 6382 3390 |
|
UK IR/PR Advisers IFC Advisory Graham Herring / Tim Metcalfe / Zach Cohen +44 203 934 6630 |
UK Brokers Oberon Capital Aimee McCusker / Adam Pollock +44 203 179 5300 aimeemccusker@oberoninvestments.com adampollock@oberoninvestments.com |
About Argent BioPharma
Argent BioPharma is dedicated to meeting unmet medical needs by combining PolyPharmacology and Nanotechnology, aspiring to be a renowned global leader in the biopharmaceutical sector. Our mission centres on researching and developing ground-breaking treatments for worldwide health issues, guided by strategic principles such as pioneering life science advancements, ensuring global access, fostering continuous innovation, and striving for industry leadership.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 23 minutes ago Helios Underwriting
- 44 minutes ago SSE
- 1 hour ago Judges Scientific
- 2 hours ago AB Dynamics
- 2 hours ago Henry Boot